Related Experiment Video
Updated: Jun 26, 2026
SUMO-Binding Entities (SUBEs) as Tools for the Enrichment, Isolation, Identification, and Characterization of the SUMO Proteome in Liver Cancer
Published on: November 1, 2019
Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design
Xinyuan Duan1, John O Trent, Hong Ye
1James Graham Brown Cancer Center, University of Louisville, 529 South Jackson Street, Louisville, Kentucky, 40202, USA.
Abstract:
Sumoylation has been implicated in a variety of cancers, suggesting that sumoylation manipulation could be one approach for regulating tumorgenesis. Ubc9 exerts a central function for the sumoylation pathway, interacting with almost all the partners required for sumoylation. The high-resolution structure available for Ubc9 as well as the recent determination of more interacting partner complex structures makes rational drug design that target Ubc9 possible. Structure-based virtual drug screening has been used increasingly as the first step of drug design to select potential lead templates. This review analyzes all the interfaces between Ubc9 and its binding partners while also highlighting the possible targeting sites on Ubc9 best suited for virtual screening and drug design.
Insights
Sumoylation is involved in cancer, and Ubc9 is key to this process. Targeting Ubc9 through drug design, aided by structural analysis, offers a potential strategy for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Sumoylation plays a role in various cancers, indicating its potential as a therapeutic target.
- Ubc9 is a crucial enzyme in the sumoylation pathway, interacting with numerous partners.
Purpose of the Study:
- To analyze Ubc9's interaction interfaces with its binding partners.
- To identify potential drug targeting sites on Ubc9 for cancer therapy.
Main Methods:
- Review of existing structural data for Ubc9 and its complexes.
- Analysis of Ubc9-interacting partner interfaces.
- Identification of druggable pockets on Ubc9.
Main Results:
- Detailed analysis of Ubc9's binding interfaces.
- Highlighting specific regions on Ubc9 suitable for drug targeting.
- Structural insights facilitate rational drug design against Ubc9.
Conclusions:
- Targeting Ubc9 is a promising strategy for cancer treatment.
- Structure-based drug design targeting Ubc9 interfaces can lead to novel therapeutics.
- Further investigation into Ubc9-targeting agents is warranted.
